secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2023-08-22T23:59:59+00:00
Accession:  0001493152-23-029841
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma gets Nasdaq extension to Feb 20, 2024 for bid price compliance
---------------------------------------------------------------------------

- Company has until Feb 20, 2024 to close at $1.00 for 10 consecutive days to regain compliance.
- May consider a reverse stock split to meet the Minimum Bid Price Requirement.
- No immediate effect on listing; common stock continues trading on Nasdaq Capital Market under GTBP.
- No assurance that compliance will be regained; company will monitor bid price and consider options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315223029841/0001493152-23-029841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315223029841/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-029841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer